Cargando…
Efficacité du traitement antirétroviral hautement actif seul dans le traitement du syndrome d'infiltration lymphocytaire diffus chez une patiente ivoirienne vivant avec le VIH : à propos d'un cas
OBJECTIVE: We report in this work the efficacy of highly active antiretrovirals (ARVs) alone in the treatment of diffuse infiltrative lymphocytosis syndrome (DILS) without the use of corticosteroids, which appears risky in patients living with HIV. OBSERVATION: This is a 60-year-old HIV-positive pat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MTSI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128493/ https://www.ncbi.nlm.nih.gov/pubmed/35686173 http://dx.doi.org/10.48327/mtsibulletin.2021.118 |
Sumario: | OBJECTIVE: We report in this work the efficacy of highly active antiretrovirals (ARVs) alone in the treatment of diffuse infiltrative lymphocytosis syndrome (DILS) without the use of corticosteroids, which appears risky in patients living with HIV. OBSERVATION: This is a 60-year-old HIV-positive patient, discovered during the etiological workup of renal failure, which revealed a non-nephrotic glomerular profile. The renal biopsy found an interstitial infiltrate of CD8 suggestive of DILS. Management consisted in starting ARV treatment alone (lamuvidine, abacavir and raltegravir) without associated corticosteroid therapy. The clinical evolution under treatment was marked by a recovery of the renal function with a creatininemia at 99 μmol/l, a regression of the proteinuria, a CD4 rate at 293/mm(3) and an HIV viral load at 533.3 copies or 1.6 log in the space of 3 months. CONCLUSION: DILS is a diffuse systemic disease in HIV patients who are usually under poor virological control. In view of the strong immunosuppression and the absence of other infiltrative diseases, it appeared to us to be risky and unjustified to add a corticosteroid therapy. |
---|